Indaptus Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 7
- Market Cap
- -
- Website
- http://indaptusrx.com
- Introduction
Intec Parent, Inc. develops pharmaceutical products. The company is headquartered in Jerusalem, Israel.
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor, AdultHCC - Hepatocellular CarcinomaCRC (Colorectal Cancer)Pancreatic AdenocarcinomaNSCLC Non-small Cell Lung CancerSquamous Cell Cancer of the Head and NeckUC (Urothelial Cancer)MSI-H Cancer
- Interventions
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Indaptus Therapeutics, Inc
- Target Recruit Count
- 120
- Registration Number
- NCT05651022
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸UH Seidman Cancer Center, Cleveland, Ohio, United States
🇺🇸University of Southern California- Norris Cancer Center, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath